OSOlga V. Sakharova

Olga V. Sakharova

*This is an algorithmically generated author record based on publicly available information.

Olga V. Sakharova has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metastatic adenocarcinoma within a functioning adrenal adenoma: a case report

    by Jeremiah T Martin, Fuad Alkhoury, Scott Helton, Paul Fiedler, Olga Sakharova, Steven Yood

    We present the case of a 54-year-old woman who underwent right adrenalectomy for palliation of Cushing's symptoms. She had recently been diagnosed with lung adenocarcinoma. Pathologic findings revealed a 5 cm adrenal adenoma with a metastatic adenocarcinoma deposit. The occurrence of tumor-to-tumor metastasis is rare, and the finding of a metastasis within a functional adrenal adenoma exceptionally so. Previously reported incidences of this finding in patients with lung cancer range from 0.14% to 0.63%. We review the literature regarding this unusual finding.


  • Pathogenesis of diabetic nephropathy: focus on transforming growth factor-β and connective tissue growth factor

    by Olga V. Sakharova, Maarten W. Taal, Barry M. Brenner

    Although considerable improvement in the prognosis of diabetic nephropathy has been achieved in recent years due to intensive insulin and angiotensin-converting enzyme inhibitor treatment, these approaches do not provide complete protection against progression of diabetic nephropathy. An urgent need for additional novel therapies to prevent or further slow the progression of diabetic nephropathy motivated us to provide an up-to-date review with particular emphasis on the potential role of two growth factors--transforming growth factor-beta and connective tissue growth factor--in the pathogenesis of diabetic nephropathy. The most intensively studied to date, transforming growth factor-beta appears to play a central role in the pathogenesis of diabetic nephropathy. Recently, attention has focused on connective tissue growth factor, which mimics the biological activity of transforming growth factor-beta in profibrotic tissue formation. Thus, acting as a downstream mediator of the profibrotic activity of transforming growth factor-beta, connective tissue growth factor may constitute a more specific target for future antifibrotic therapies.